ALT has undergone a major strategic pivot from obesity-focused drug development to liver disease specialization, accompanied by significant balance sheet expansion suggesting major financing activity.
The company has fundamentally repositioned itself as a "late clinical-stage" liver disease specialist, dropping obesity from its core focus and emphasizing alcohol-related liver conditions alongside MASH. This represents a material shift in business strategy and target markets that could significantly impact the investment thesis and competitive positioning.
ALT's financials reflect a transformational period with total assets doubling to $279.9M and current assets surging 103% to $278.2M, indicating substantial capital raising activity. Total liabilities spiked 248% to $55.0M while stockholders' equity increased 82% to $224.9M, and the outstanding share count nearly doubled from 77M to 130M shares, confirming a major equity financing round. Despite this capital infusion, R&D expenses declined 19% to $66.4M, suggesting either improved operational efficiency or a temporary lull in development spending as the company executes its strategic pivot.
Interest expense surged 337.5% — significant debt increase or rising rates materially impacting earnings.
Liabilities grew 248.4% — significant increase in debt or obligations, assess impact on financial flexibility.
Strong top-line growth of 105% — accelerating demand or successful expansion into new markets.
Current assets grew 102.7% — improving short-term liquidity or inventory/receivables build.
Asset base grew 100.9% — expansion through organic growth, acquisitions, or capital deployment.
Equity base grew 82.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Capex reduced 76.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current liabilities surged 43.3% — significant near-term obligations; verify ability to meet short-term debt.
R&D spending cut 19.2% — could signal cost discipline or concerning reduction in innovation investment.
Cash grew 18.5% — improving liquidity position supports investment and shareholder returns.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →